Moderna reported a Q2 loss of $2.13 per share on $142M in revenue, beating consensus estimates. The company lowered 2025 revenue guidance to $1.5B-$2.2B due to U.K. delivery shifts to Q1 2026 and announced a planned 10% workforce reduction. Moderna’s product sales were down 38% year over year to $114 million, primarily due to lower Spikevax sales. Operating costs declined due to cost-cutting activities. The company expects to end 2025 with cash, cash equivalents, and investments of nearly $6 billion. Moderna secured several regulatory approvals from the FDA and is evaluating pipeline candidates in late-stage development.

Read more at Zacks Investment Research: MRNA Beats on Q2 Earnings & Sales, Stock Down on Lowered Sales View – August 1, 2025